HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting the transcriptional activity of STAT3 by a novel fusion protein.

AbstractBACKGROUND:
The continuous activation of transcription factors drives many diseases, including tumors, autoimmune disease, neurodegenerative disease, and male infertility. Thus, Blocking the transcriptional activity of these proteins may inhibit disease progression. In this study, we developed a new method to specifically inhibit the activity of the transcription factor STAT3.
METHODS:
Fusing the transcriptional inhibitory domain KRAB with STAT3 successfully blocked the transcription activity of STAT3 in cancer cells without affecting its function in the mitochondria and lysosomes.
RESULTS:
the expression of KRAB-STAT3 fusion protein inhibited the growth of tumor cells.
CONCLUSIONS:
The KRAB-STAT3 fusion protein provides a novel approach for drug development for the treatment of cancer or autoimmune diseases.
AuthorsYanqiong Chen, Wenting Zhang, Xiufeng Bai, Yi Liu
JournalBMC cancer (BMC Cancer) Vol. 22 Issue 1 Pg. 751 (Jul 10 2022) ISSN: 1471-2407 [Electronic] England
PMID35810312 (Publication Type: Journal Article)
Copyright© 2022. The Author(s).
Chemical References
  • STAT3 Transcription Factor
  • STAT3 protein, human
Topics
  • Gene Expression Regulation
  • Humans
  • Male
  • Neoplasms (pathology)
  • Neurodegenerative Diseases
  • STAT3 Transcription Factor (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: